Vesnarinone
From Wikipedia, the free encyclopedia
| This article does not cite any sources. (November 2014) |
| Systematic (IUPAC) name | |
|---|---|
|
6-[4-(3,4-dimethoxybenzoyl)piperazin-1-yl]-3,4-dihydro-1H-quinolin-2-one
|
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration |
Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 81840-15-5 |
| ATC code | none |
| PubChem | CID 5663 |
| ChemSpider | 5461 |
| UNII | 5COW40EV8M |
| ChEMBL | CHEMBL17423 |
| Chemical data | |
| Formula | C22H25N3O4 |
| Molar mass | 395.45 g/mol |
|
|
|
|
| |
Vesnarinone (INN) is a cardiotonic agent. A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure.
|
|
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |

